Swedish Orphan Biovitrum AB (Sobi) (STO:SOBI), a specialised international biopharmaceutical company focused on treatment of rare diseases, announced on Wednesday that it will commence a short-term clinical study to evaluate the efficacy and safety of anakinra and emapalumab in the treatment of hyper-inflammatory syndrome, one of the most serious complications associated with severe COVID-19 disease.
Reportedly, this is in response to a request from the National Institute for Infectious Diseases, the organisation which is acting as the coordinating site for the SARS-CoV-2 epidemic in Italy.
These products, which are currently used in the treatment of rare diseases, have been considered for investigation as a result of emerging data and observations made by Italian physicians treating patients with COVID-19. A summary of the study protocol will be published on clinicaltrials.gov.
Patients who are treated or who may need treatment with emapalumab and anakinra for approved indications will not be impacted, the company added.
Sobi provides sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications.
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins